Evidence map›Paper›PMID 31740640›Full record

ReviewVision (Basel, Switzerland)2017

The Role of the P2X7 Receptor in Ocular Stresses: A Potential Therapeutic Target.

Mélody Dutot, Elodie Olivier, Anaïs Wakx, Patrice Rat

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vision (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Role of Purinergic Receptors in the Circadian System.International journal of molecular sciences · 2020
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mélody DutotUMR 8638 CNRS COMETE, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006 Paris, France.
Elodie OlivierUMR 8638 CNRS COMETE, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006 Paris, France.
Anaïs WakxUMR 8638 CNRS COMETE, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006 Paris, France.
Patrice RatUMR 8638 CNRS COMETE, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie, 4 Avenue de l'Observatoire, 75006 Paris, France.
Délégation Paris 5 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The P2X7 receptor is expressed in both anterior and posterior segments of the eyeball. In the ocular surface, the P2X7 receptor is activated in case of external aggressions: preservatives and surfactants induce the activation of P2X7 receptors, leading to either apoptosis, inflammation, or cell proliferation. In the retina, the key endogenous actors of age-related macular degeneration, diabetic retinopathy, and glaucoma act through P2X7 receptors' activation and/or upregulation of P2X7 receptors' expression. Different therapeutic strategies aimed at the P2X7 receptor exist. P2X7 receptor antagonists, such as divalent cations and Brilliant Blue G (BBG) could be used to target either the ocular surface or the retina, as long as polyunsaturated fatty acids may exert their effects through the disruption of plasma membrane lipid rafts or saffron that reduces the response evoked by P2X7 receptor stimulation. Treatments against P2X7 receptor activation are proposed by using either eye drops or food supplements.

Indexed as

modulationocularP2X7 receptorstresstherapeutic target

Identifiers

PMID31740640
PMCPMC6835678
OpenAlexW2615488998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.